Top

Published in:

01-01-2009 | Original Article

Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis

Authors: Jacob N. Ablin, Zacharinka Goldstein, Valerie Aloush, Hagit Matz, Ori Elkayam, Dan Caspi, Shmuel Swartzenberg, Jacob George, Yonit Wohl

Published in: Rheumatology International | Issue 3/2009

Abstract

Endothelial progenitor cells (EPCs) are a population of bone marrow derived cells which have been attributed with the ability to migrate into areas of tissue ischemia and to posses reparative qualities. EPCs have been shown to be decreased in level and function in various inflammatory disorders. Psoriasis and psoriatic arthritis are associated with an increase in cardiovascular morbidity. The aim of the study was to investigate the number of EPCs among patients suffering from psoriasis and psoriatic arthritis. Patients suffering from active psoriasis and psoriatic arthritis were recruited as well as healthy controls. Disease activity was assessed with the DAS-28, BASDAI and PASI scores. Peripheral blood mononuclear cells were isolated and EPC numbers evaluated by FACS analysis using the CD34/133 and CD34/KDR. No significant difference was found between numbers of EPCs between healthy controls, patients with psoriasis and psoriatic arthritis. A significant correlation was found between levels of VGEF and the BASDAI score. The results of the current study do not support a significant role for EPCs in the pathogenesis of psoriasis and psoriatic arthritis.

Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA et al (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600. doi:10.1056/NEJMoa022287 PubMedCrossRef

George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A et al (2004) Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 25(12):1003–1008. doi:10.1016/j.ehj.2004.03.026 PubMedCrossRef

George J, Hertz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A et al (2003) Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 23(12):e57–e60. doi:10.1161/01.ATV.0000107029.65274.db PubMedCrossRef

Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D et al (2005) Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 111(2):204–211. doi:10.1161/01.CIR.0000151875.21836.AE PubMedCrossRef

Ablin JN, Boguslavski V, Aloush V, Elkayam O, Paran D, Caspi D et al (2006) Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. Life Sci 75(25):2364–2369. doi:10.1016/j.lfs.2006.07.035 CrossRef

Schon MP, Boehncke W (2005) Psoriasis. N Engl J Med 352(18):1899–1912. doi:10.1056/NEJMra041320 PubMedCrossRef

Goffe B (2004) Etanercept (Enbrel)—an update. Skin Therapy Lett 9(10):1–4PubMed

Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Etanercept Psoriasis Study Group et al (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 20(349):21

Mease PJ (2005) Psoriatic arthritis therapy advances. Curr Opin Rheumatol 17(4):426–432. doi:10.1097/01.bor.0000166382.96024.85 PubMedCrossRef

10.

Rosenzweig A (2003) Endothelial progenitor cells. N Engl J Med 348(7):581–582. doi:10.1056/NEJMp020175 PubMedCrossRef

11.

Ingram DA, Caplice NM, Yoder MC (2005) Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 106(5):1525–1531. doi:10.1182/blood-2005-04-1509 PubMedCrossRef

12.

Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S et al (2005) Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18):2356–2363. doi:10.1161/01.CIR.0000164260.82417.3F PubMedCrossRef

13.

Dulic-Sills A, Blunden MJ, Mawdsley J, Bastin AJ, McAuley D, Griffiths M et al (2006) New flow cytometric technique for the evaluation of circulating endothelial progenitor cell levels in various disease groups. J Immunol Methods 316(1–2):107–115. doi:10.1016/j.jim.2006.08.011 PubMedCrossRef

14.

George J, Shmilovich H, Deutsch V, Pick M, Miller H, Keren G et al (2006) Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng 12(2):331–335. doi:10.1089/ten.2006.12.331 PubMedCrossRef

15.

Allanore Y, Batteux F, Avouac J, Assous N, Weill B, Kahan A (2007) Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 25(1):60–66PubMed

16.

Masuda J, Mitsuyama K, Yamasaki H, Takedatsu H, Okamura T, Andoh A et al (2007) Depletion of endothelial progenitor cells in the peripheral blood of patients with ulcerative colitis. Int J Mol Med 19(2):221–228PubMed

17.

Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMed

18.

Anandarajah AP, Ritchlin CT (2004) Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 16(4):338–343. doi :10.1097/01.bor.0000129718.13939.81<PubMedCrossRef

19.

Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34(3):585–592. doi:10.1016/j.semarthrit.2004.07.010 PubMedCrossRef

20.

Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC (2007) Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 66(7):865–870. doi:10.1136/ard.2006.065631 PubMedCrossRef

21.

Fadini GP, Agostini C, Sartore S, Avogaro A (2007) Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 194(1):46–54. doi:10.1016/j.atherosclerosis.2007.03.046 PubMedCrossRef

22.

van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE (2006) Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 8(5):R151. doi:10.1186/ar2045 PubMedCrossRef

23.

Georgiadis AN, Voulgari PV, Argyropoulou MI, Alamanos Y, Elisaf M, Tselepis AD et al (2008) Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. Semin Arthritis Rheum 38(1):13–19PubMedCrossRef

24.

Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33(11):2167–2172PubMed

25.

Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y et al (2007) Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 36(4):203–209. doi:10.1016/j.semarthrit.2006.09.001 PubMedCrossRef

26.

Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al (2007) Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 15(57):287–293. doi:10.1002/art.22530 CrossRef

27.

Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Säemann M et al (2007) Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis 66(10):1284–1288. doi:10.1136/ard.2006.066605 PubMedCrossRef

28.

Shantsila E, Watson T, Tse HF, Lip GY (2007) Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell numbers. Ann Med 39(6):474–479. doi:10.1080/07853890701329283 PubMedCrossRef

29.

Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 109:1801–1809PubMedCrossRef

Title: Normal levels and function of endothelial progenitor cells in patients with psoriatic arthritis
Authors: Jacob N. Ablin
Zacharinka Goldstein
Valerie Aloush
Hagit Matz
Ori Elkayam
Dan Caspi
Shmuel Swartzenberg
Jacob George
Yonit Wohl
Publication date: 01-01-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 3/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0676-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2009

Strontium ranelate decreases plasma homocysteine levels in postmenopausal osteoporotic women

Polymyositis-like syndrome caused by hypothyroidism, presenting as camptocormia

Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis

Health-related quality of life in patients with common rheumatic diseases referred to a university clinic

N-terminal pro-brain natriuretic peptide in systemic sclerosis related pulmonary arterial hypertension under bosentan treatment

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials